SCA
AVEO

SAC Capital Advisors’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

SAC Capital Advisors’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-50,000
Closed -$748K – 1248
2014
Q1 		$748K Buy
+50,000
New +$898K ﹤0.01% 1044

Other funds holding AVEO

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
DVC
Deer VI & Co Larchmont, New York $2.23M AUM 9.32% 1-Year Est. Return

SAC Capital Advisors's AVEO Position: Q2 2014 in Review

SAC Capital Advisors sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2014, closing a stake of 50,000 shares — an estimated $748K sold.

SAC Capital Advisors first reported a position in AVEO in Q1 2014 and held it in 1 quarter. The position peaked at $748K in Q1 2014. 61 funds tracked by Wall St. Rank hold AVEO as of Q2 2014.

  • SAC Capital Advisors reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 50,000 AVEO Pharmaceuticals, Inc. shares in Q2 2014, an estimated $748K.
  • SAC Capital Advisors first reported a position in AVEO Pharmaceuticals, Inc. in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's AVEO Pharmaceuticals, Inc. position peaked at $748K in Q1 2014.
  • 61 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.